

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: September 3, 2004

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	Unassigned
Filing Date	09/03/2004
First Named Inventor	David M. EVANS
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	052209-0124

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

/CC/	A1		WO 95/07291		FERRING BV	3/16/1995		
------	----	--	-------------	--	------------	-----------	--	--

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
--------------------	-----------------------	--	----------------

/CC/	A2	International Search Report	
	A3	T. Griesbacher et al., "Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats", British Journal of Pharmacology, vol. 137, no. 5, November 2002, pp. 692-700, XP002252617, Basingstoke, Hants., GB ISSN: 0007-1188 the whole document.	
	A4	W.C. Wolf et al., "A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness", American Journal of Pathology, vol. 159, no. 5, November 2001, pp. 1797-1805, XP002252618, Philadelphia PA, US, ISSN: 0002-9440 the whole document.	
	A5	K.D. BHOOLA et al., "Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases", Pharmacological Reviews, Vol. 44, No. 1, 1992, pp. 1-80.	
	A6	D. Michael EVANS et al., "Selective Inhibitors of Plasma Kallikrein", Immunopharmacology, 32 (1996) pp. 115-116.	
	A7	D. Michael EVANS et al., "Synthetic Inhibitors of Human Tissue Kallikrein", Immunopharmacology, 32 (1996), pp. 117-118.	
	A8	J. STURZEBECHER et al., "Novel Plasma Kallikrein Inhibitors of the Benzamidine Type", Brazilian J Med Biol Res (1994) 27, pp. 1929-1934.	
	A9	Naoki TENO et al., "Development of Active Center-Directed Plasmin and Plasma Kallikrein Inhibitors and Studies on the Structure-Inhibitory Activity Relationship", Chem. Pharma. Bull. 41(6) pp. 1079-1090 (1993).	
	A10	Y. FUJIMORI et al., "Effects of a Highly Selective Plasma Kallikrein Inhibitor on Collagen-Induced Arthritis in Mice", Agents Actions, 39, (1993), pp. 42-48.	
/CC/	A11	S. OKAMOTO et al., "A Finding of Highly Selective Synthetic Inhibitor of Plasma Kallikrein: It's Action to Bradykinin Generation, Intrinsic Coagulation and Experimental DIC", Recent Progress on Kinins, 1992, pp. 198-204.	

Examiner
Signature

/Celia Chang/

Date

Considered

04/02/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: September 3, 2004

(use as many sheets as necessary)

Complete if Known

Application Number	Unassigned
Filing Date	09/03/2004
First Named Inventor	David M. EVANS
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	052209-0124

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/CC/	A12	Antoni STADNICKI MD et al., "Selective Plasma Kallikrein Inhibitor Attenuates Acute Intestinal Inflammation in Lewis Rat", Digestive Diseases and Sciences, Vol. 41, No. 5, May 1996, pp. 912-920.	
	A13	J. Sueras-Diaz et al., "Cleavage of human Kininogen fragments at Met-Kys by human tissue kallikrein", Brazilian J Med Biol Res (1994) 27: 1935-1942.	
	A14	H.T. Johansen et al., "Assay of Kallikrein Inhibitors and Leves of Acetone-Activated Kallikrein in Plasma Specimens from Reactors to Dextran or to Contrast Media", INT. J. TISS. REAC. VIII(3), pp. 185-192, (1986).	
	A15	Deepak K. SHORI et al., "New Specific Assays for Tonin and Tissue Kallikrein Activities in Rat Submandibular Glands", Biochemical Pharmacology, Vol. 43, No. 6, pp. 1209-1217, 1992.	
	A16	Jörg STÜRZBECHER et al., "Inhibition of Human Mast Cell Tryptase by Benzamidine Derivatives", Biol. Chem. Hoppe-Seyler, Vol. 373, pp. 1025-1030, October 1992.	
/CC/	A17	M. DIXON, "The Determination of Enzyme Inhibitor Constants", Biochemical Laboratory, University of Cambridge, Vol. 55, pp. 170-171, 1953.	

Examiner
Signature

/Celia Chang/

Date
Considered

04/02/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.